65,437 trials
Hepatitis C
Primary: Percentage of Participants With Sustained Virologic Response 12 (SVR12) — 28.6; 57.1 Percentage of participants
Visual Acuity
Primary: Ocular Comfort — 81.96; 82.49 Units on a scale
Cushing's Disease · Acromegaly
Primary: Change in HbA1c From Randomization to Approximately 16 Weeks — -0.12; 0.26; 0.33; 0.45 Hba1c percentage
Stage IV Pancreatic Cancer
Primary: Complete Response Rate — 2; 15; 4; 3 Participants
Adult Stem Cell Proliferation
Primary: Percentage of CD133+ Cells — 0.50; 0.28; 0.54; 0.47 percent of total
Myopia
Primary: Comfort — 90; 89; 86; 87 score on a scale
Psoriasis
Primary: Percentage of Participants Achieving 90% Improvement Psoriasis Area and Severity Index (PASI) Score (PASI90) From Baseline to Week 16 — 2.0; 73.2 percentage of…
Respiratory Failure
Primary: Rate of Intubation — 10; 23 participants
Heart Failure
Primary: Median Urine Output at 24 Hours Post Randomization — 2910; 3150 mL
Rheumatoid Arthritis
Primary: Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12 — 30.7; 35.6; 42.5; 30.8 Percentage of participants — p=0.5224
Asthma
Primary: Part A: Number of Participants With Any Non-serious Adverse Event (nSAE) and Any Serious Adverse Event (SAE) — 6; 9; 6; 7 Participants
Cardiovascular Diseases · Heart Diseases
Primary: Physical Environment Factors Using Geographic Information Systems [GIS] — 1.3; 1.9; -2.1; -1.6 units on a scale
Breast Cancer
Primary: Number of Dose Limiting Toxicities (DLT) of IT Trastuzumab in Sequential Cohorts of Escalating Doses for Patients With Leptomeningeal Metastases in HER2+ Breast Cancer…
Heart Failure
Primary: Percentage of Successful"In-Clinic LVAT" Test — 94.66 percentage of successful LVAT test
Psoriatic Arthritis
Primary: Number of Participants With Adverse Events — 87; 22; 1; 7 participants